Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Perampanel Tablet Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects

NCT01396590
View directory record Official record
Conditions
Healthy
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

NCT04497142
View directory record Official record
Conditions
Glioma, Malignant, Surgery, Seizures
Interventions
Perampanel, Standard of Care
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder

NCT04502589
View directory record Official record
Conditions
Alcohol Disorders
Interventions
Perampanel Tablet, Disulfiram
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 8, 2026, 6:29 PM EDT
Terminated Not applicable Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT03020797
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Perampanel, Placebo Oral Tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 4 Interventional Results available

Fycompa Titration Intervals and Effects on Retention Rate

NCT03457129
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel Oral Tablet
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

NCT01396577
View directory record Official record
Conditions
Healthy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability of Perampanel in Cervical Dystonia

NCT02131467
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Perampanel
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

NCT03376997
View directory record Official record
Conditions
Healthy Participants
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Early Phase 1 Interventional

Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

NCT03793868
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Perampanel, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 8, 2026, 6:29 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141
View directory record Official record
Conditions
Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions
Perampanel Oral Suspension, Perampanel Tablet
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699972
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 8, 2026, 6:29 PM EDT
Terminated Phase 2 Interventional Results available

A Study of E2007 In Patients With Parkinson's Disease

NCT00427011
View directory record Official record
Conditions
Parkinson's Disease
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Peoria, Arizona • Little Rock, Arkansas • Oxnard, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 8, 2026, 6:29 PM EDT
Not listed Phase 2 Interventional

Fycompa in Subjects With Small Fiber Neuropathy (SFN)

NCT02511873
View directory record Official record
Conditions
Neuropathy, Small Fiber
Interventions
Fycompa, Placebo
Drug
Lead sponsor
PNA Center for Neurological Research
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129
View directory record Official record
Conditions
Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

NCT01161524
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Aurora, Colorado • Gulf Breeze, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 8, 2026, 6:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

NCT00505284
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Placebo, E2007 (2 mg), E2007 (4 mg), E2007 (6 mg), E2007 (8 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 8, 2026, 6:29 PM EDT